Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Triple Negative Breast Cancer
Interventions: BIOLOGICAL: pembrolizumab|DRUG: capecitabine|DRUG: eribulin|DRUG: gemcitabine|DRUG: vinorelbine
Sponsor: Merck Sharp & Dohme LLC